» Articles » PMID: 24846373

A Novel Algorithm to Assess Risk of Heart Failure Exacerbation Using ICD Diagnostics: Validation from RAFT

Overview
Journal Heart Rhythm
Publisher Elsevier
Date 2014 May 22
PMID 24846373
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The integrated diagnostics (ID) algorithm is an implantable device-based tool that collates data pertaining to heart rhythm, heart rate, intrathoracic fluid status, and activity, producing a risk score that correlates with 30-day risk of heart failure (HF) hospitalization.

Objective: We sought to validate the ID algorithm using the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial.

Methods: Diagnostic measures of the algorithm include OptiVol fluid index, nighttime heart rate, minutes of patient activity, heart rate variability, and combined measure of cardiac rhythm and biventricular pacing. Monthly evaluations of ID parameters were assessed for the development of HF symptoms and hospitalization for HF.

Results: A total of 1224 patients were included: 741 (61%) with cardiac resynchronization therapy with defibrillator devices and 483 (39%) with implanted cardioverter-defibrillator only. The mean age was 66 ± 9 years, and 1013 (83%) were men. A total of 37,861 months of follow-up data were available, with 258 HF hospitalizations (event rate 0.68% per month). There were 33 HF hospitalizations during low-risk months (0.21% per month), 123 during medium-risk months (0.66% per month), and 102 during high-risk months (2.61% per month). Compared with low-risk months, and 95% confidence intervals) of HF hospitalizations during medium-risk months was 2.9 (2.0-4.4) and during high-risk months was 10.7 (6.9-16.6). Multivariable analysis demonstrated that each ID variable had independent association with HF hospitalization.

Conclusion: The risk of HF as determined by the ID algorithm correlated with HF hospitalization and several HF signs and symptoms among patients in the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial. This may present a useful adjunct to detect early signs of HF and adjust therapy to reduce morbidity and costs involved with hospital admission.

Citing Articles

Efficacy of the Cardiac Implantable Electronic Device Multisensory Triage-HF Algorithm in Heart Failure Care: A Real-World Clinical Experience.

Aslan U, Beeres S, Feijen M, Mulder G, Jukema J, Egorova A Sensors (Basel). 2024; 24(11).

PMID: 38894453 PMC: 11175325. DOI: 10.3390/s24113664.


Association of a device-based remote management heart failure pathway with outcomes: TriageHF Plus real-world evaluation.

Ahmed F, Sammut-Powell C, Martin G, Callan P, Cunnington C, Kahn M ESC Heart Fail. 2024; 11(5):2637-2647.

PMID: 38712903 PMC: 11424317. DOI: 10.1002/ehf2.14821.


Validation of a Heart Failure Risk Score in a Cohort of Cardiac Resynchronization Therapy Patients Under Remote Monitoring: Results from the TriageHF™ Algorithm.

Cardoso I, Silva Cunha P, Laranjo S, Grazina A, Miguel Viegas J, Portugal G J Innov Card Rhythm Manag. 2023; 14(9):5576-5581.

PMID: 37781719 PMC: 10540879. DOI: 10.19102/icrm.2023.14093.


Integration of a Smartphone HF-Dedicated App in the Remote Monitoring of Heart Failure Patients with Cardiac Implantable Electronic Devices: Patient Access, Acceptance, and Adherence to Use.

Ziacchi M, Molon G, Giudici V, Botto G, Viscusi M, Brasca F J Clin Med. 2023; 12(17).

PMID: 37685593 PMC: 10488122. DOI: 10.3390/jcm12175528.


Cardiovascular Implantable Electronic Devices Enabled Remote Heart Failure Monitoring; What We Have Learned and Where to Go Next.

Assa S, Vernooy K, van Stipdonk A J Cardiovasc Dev Dis. 2023; 10(4).

PMID: 37103031 PMC: 10142884. DOI: 10.3390/jcdd10040152.